Search

Your search keyword '"Louis Regis Dossou-Yovo"' showing total 2 results
Start Over Author "Louis Regis Dossou-Yovo" Journal malaria journal
2 results on '"Louis Regis Dossou-Yovo"'

1. Molecular surveillance of the Pfmdr1 N86Y allele among Congolese pregnant women with asymptomatic malaria

Author

Louis Regis Dossou-Yovo, Francine Ntoumi, Felix Koukouikila-Koussounda, Jeannhey Christevy Vouvoungui, Ayodele Adedoja, David Nderu, Thirumalaisamy P. Velavan, and Arsène Lenga

Subjects
Plasmodium falciparum, Pfmdr1, Antimalarial drug resistance, Lumefantrine, Brazzaville, Republic of Congo, Arctic medicine. Tropical medicine, RC955-962, Infectious and parasitic diseases, RC109-216
Abstract

Abstract Background Malaria in pregnancy is associated with considerable morbidity and mortality. Regular surveillance of artemisinin-based combination therapy tolerance, or molecular makers of resistance, is vital for effective malaria treatment, control and eradication programmes. Plasmodium falciparum multiple drug resistance-1 gene (Pfmdr1) N86Y mutation is associated with reduced susceptibility to lumefantrine. This study assessed the prevalence of Pfmdr1 N86Y in Brazzaville, Republic of Congo. Methods A total 1001 of P. falciparum-infected blood samples obtained from asymptomatic malaria pregnant women having a normal child delivery at the Madibou Integrated Health Centre were analysed. Pfmdr1 N86Y genotyping was conducted using PCR-restriction fragment length polymorphism. Results The wild type Pfmdr1 N86 allele was predominant (> 68%) in this study, whereas a few isolates carrying the either the mutant allele (Pfmdr1 86Y) alone or both alleles (mixed genotype). The dominance of the wildtype allele (pfmdr1 N86) indicates the plausible decline P. falciparum susceptibility to lumefantrine. Conclusion This study gives an update on the prevalence of Pfmdr1 N86Y alleles in Brazzaville, Republic of Congo. It also raises concern on the imminent emergence of resistance against artemether–lumefantrine in this setting. This study underscores the importance to regular artemether–lumefantrine efficacy monitoring to inform the malaria control programme of the Republic of Congo.

Published
2020
Full Text
View/download PDF

2. Malaria burden and anti-malarial drug efficacy in Owando, northern Congo

Author

Bruno Pradines, Brunelle Diassivy Matondo, Hervé Bogreau, Prisca Nadine Casimiro, Mathieu Ndounga, Louis Regis Dossou-Yovo, Rigobert Mbouka, Leonardo K. Basco, Kim Yen Ha Nguyen, Brice Pembet Singana, Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes (URMITE), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR48, INSB-INSB-Centre National de la Recherche Scientifique (CNRS), Centre National de Référence du Paludisme, and Institut des sciences biologiques (INSB-CNRS)-Institut des sciences biologiques (INSB-CNRS)-Centre National de la Recherche Scientifique (CNRS)

Subjects
0301 basic medicine, Male, medicine.medical_specialty, 030106 microbiology, 030231 tropical medicine, Plasmodium falciparum, Drug resistance, Rapid diagnostic test, Polymerase Chain Reaction, Efficacy, 03 medical and health sciences, Antimalarials, Congo-Brazzaville, 0302 clinical medicine, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Internal medicine, Epidemiology, parasitic diseases, Medicine, Humans, Artemisinin, Combination therapy, Child, Microscopy, biology, business.industry, Research, Infant, Newborn, Infant, biology.organism_classification, medicine.disease, Virology, 3. Good health, Malaria, Infectious Diseases, Parasitology, Congo, Child, Preschool, Female, business, Anti-malarial drug, medicine.drug
Abstract

Background In the Republic of Congo, previous epidemiological studies have only been conducted in the south of the country where it is most accessible. Nationally representative data on the efficacy of new anti-malarial tools are lacking in the country. As an initial step to close the gap, clinical efficacy of two artemisinin-based combinations, artesunate-amodiaquine (ASAQ) and artemether-lumefantrine (AL), was assessed in Owando, a city in equatorial flooded forest in northern Republic of Congo. Methods Under 12 years old febrile children attending public health facilities were screened for malaria parasites using lactate dehydrogenase (LDH)-based rapid diagnostic test (RDT) for malaria and microscopic examination of thick blood films. Patients with at least 1,000 asexual Plasmodium falciparum parasites/µl of blood were clinically examined, included after informed consent, and followed up for 28 days, according to the 2009 World Health Organization protocol. Patients were randomly assigned to co-formulated ASAQ (Coarsucam®) or AL (Coartem®) treatment groups. Plasmodium falciparum recrudescent isolates were compared to pre-treatment isolates by polymerase chain reaction (PCR) using msp1, msp2, and glurp genes to distinguish between re-infection and recrudescence. Results Between November 2012 and February 2013, 857 under 12 years old febrile children were screened, of whom 198 (23.1 %) had positive RDT and 167 (19.5 %) positive thick films. ASAQ and AL efficacies were 92.7 and 94.2 % before PCR correction, respectively. After genotyping, the overall efficacy was 100 % for ASAQ and 98.0 % for AL. Conclusion The data reported here represent partially the burden of malaria in 0–11 years old febrile children examined in public health centres of Owando city and serve as reference for further studies. Both artemisinin-based combinations were highly efficacious in patients under 12 years old with acute uncomplicated malaria. ASAQ was associated with more adverse events, which may reduce compliance in unsupervised treatment. Trial registration: ACTRN12612000940875

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results